Gerl A, Clemm C, Lamerz R, Mann K, Wilmanns W
Medizinische Klinik III, Klinikum Grosshadern, Ludwig-Maximilians-Universität München, F.R.G.
Eur J Cancer. 1993;29A(7):961-5. doi: 10.1016/s0959-8049(05)80202-3.
86 unselected patients with poor risk metastatic non-seminomatous germ cell tumours (NSGCT) treated from 1979 to 1990 at a single institution were reviewed with regard to the prognostic relevance of tumour marker analysis. The number of elevated tumour markers was not able to distinguish patients into prognostic subgroups. Pretreatment levels of human chorionic gonadotropin (HCG), alpha-fetoprotein (AFP) and lactate dehydrogenase (LDH) did not have a significant influence on clinical outcome. HCG and AFP half-life analysis during the first chemotherapy cycles also failed to define prognostic subgroups. If early deaths within 90 days after the onset of chemotherapy were excluded, patients with a half-life of HCG decline greater than 3.5 days tended to have a poorer prognosis which did not reach significance.
对1979年至1990年在单一机构接受治疗的86例未选择的低风险转移性非精原细胞瘤性生殖细胞肿瘤（NSGCT）患者进行了回顾，以分析肿瘤标志物分析的预后相关性。肿瘤标志物升高的数量无法将患者区分为预后亚组。人绒毛膜促性腺激素（HCG）、甲胎蛋白（AFP）和乳酸脱氢酶（LDH）的预处理水平对临床结果没有显著影响。在第一个化疗周期中对HCG和AFP半衰期的分析也未能确定预后亚组。如果排除化疗开始后90天内的早期死亡病例，HCG半衰期下降大于3.5天的患者预后往往较差，但未达到显著水平。
